Advanced search
Publication Cover
OncoImmunology Volume 10, 2021 - Issue 1
Submit an article Journal homepage
4,726
Views
45
CrossRef citations to date
0
Altmetric
Original Research

YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non–small-cell lung cancer

Kazuo Tsuchiyaa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan;b Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Katsuhiro Yoshimuraa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan;b Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Yusuke Inouea Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, Japan;b Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Yuji Iwashitaa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Hidetaka Yamadaa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Akikazu Kawasec First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Takuya Watanabed Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, JapanView further author information
,
Masayuki Tanahashid Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, JapanView further author information
,
Hiroshi Ogawae Department of Pathology, Seirei Mikatahara General Hospital, Hamamatsu, JapanView further author information
,
Kazuhito Funaic First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Kazuya Shinmuraa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
,
Takafumi Sudab Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, JapanView further author information
&
Haruhiko Sugimuraa Department of Tumor Pathology, Hamamatsu University School of Medicine, Hamamatsu, JapanCorrespondence[email protected]
View further author information
 show all
Article: 1962656 | Received 16 Apr 2021, Accepted 26 Jul 2021, Published online: 10 Aug 2021

Citations (45)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Yu Zhang, Xue-Li Wang, Jing-Jing Liu, Zhen-Yuan Qian, Zheng-Yang Pan, Ni-Ping Song, Hui-Yan Chen, Wei Zhang & Xin Zhang. (2023) ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment. Journal of Inflammation Research 16, pages 977-992.
Read now
Yongfei Fan, Yong Zhou, Ming Lou, Xinwei Li, Xudong Zhu & Kai Yuan. (2022) m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer. Journal of Inflammation Research 15, pages 1969-1989.
Read now

Articles from other publishers (43)

Iwona Ziółkowska-Suchanek & Magdalena Żurawek. (2024) FOXP3: A Player of Immunogenetic Architecture in Lung Cancer. Genes 15:4, pages 493.
Crossref
Jun-Jie Shen, Min-Chang Li, Shao-Qi Tian & Wen-Ming Chen. (2024) Long non-coding RNA GATA6-AS1 is mediated by N6-methyladenosine methylation and inhibits the proliferation and metastasis of gastric cancer. World Journal of Gastrointestinal Oncology 16:3, pages 1019-1028.
Crossref
Wei Bo, Ning Yu, Xiaokai Wang, Chun Wang & Chunying Liu. (2024) Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis. Neoplasia 48, pages 100960.
Crossref
Tongxuan Wen, Tong Li, Yeqiu Xu, Yuanzhuang Zhang, Hai Pan & Yong Wang. (2023) The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing. Cell Communication and Signaling 21:1.
Crossref
De Hu, Hidetaka Yamada, Katsuhiro Yoshimura, Tsutomu Ohta, Kazuo Tsuchiya, Yusuke Inoue, Kazuhito Funai, Takafumi Suda, Yuji Iwashita, Takuya Watanabe, Hiroshi Ogawa, Nobuhito Kurono, Kazuya Shinmura & Haruhiko Sugimura. (2023) High Expression of Fas-Associated Factor 1 Indicates a Poor Prognosis in Non-Small-Cell Lung Cancer. Current Oncology 30:11, pages 9484-9500.
Crossref
Jiaxiang Hu, Chen Xue & Qingqing Wang. (2023) N6-methyladenosine modification: an important player in the tumor immune microenvironment. Biomedicine & Pharmacotherapy 165, pages 115171.
Crossref
Qingyu Lin, Xingwen Wang & Ying Hu. (2023) The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells. Cancer Letters 569, pages 216318.
Crossref
Gang Chen, Dandan Ren, Yuanhan Wang, Hui Wang, Junhong Zhang & Song Yang. (2023) YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer. Journal of Molecular Histology 54:4, pages 365-377.
Crossref
Chenggang Gao, Jiaoshun Chen, Jianwei Bai, Haoxiang Zhang, Yanyi Tao, Shihong Wu, Hehe Li, Heshui Wu, Qiang Shen & Tao Yin. (2023) High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment. Journal of Translational Medicine 21:1.
Crossref
Weikun Zhang, Tingting Wu, Yuejiao Zhang, Wenjing Kang, Chenyu Du, Qidong You, Xuetao Chen & Zhengyu Jiang. (2023) Targeting m6A binding protein YTHDFs for cancer therapy. Bioorganic & Medicinal Chemistry 90, pages 117373.
Crossref
Ke Li, Quan Gong, Xu-Dong Xiang, Gang Guo, Jia Liu, Li Zhao, Jun Li, Nan Chen, Heng Li, Li-Juan Zhang, Chun-Yan Zhou, Zhi-Yong Wang & Li Zhuang. (2023) HNRNPA2B1-mediated m6A modification of lncRNA MEG3 facilitates tumorigenesis and metastasis of non-small cell lung cancer by regulating miR-21-5p/PTEN axis. Journal of Translational Medicine 21:1.
Crossref
Jean B. Bertoldo, Simon Müller & Stefan Hüttelmaier. (2023) RNA-binding proteins in cancer drug discovery. Drug Discovery Today 28:6, pages 103580.
Crossref
Jing Yang, Jin Xu, Wei Wang, Bo Zhang, Xianjun Yu & Si Shi. (2023) Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets. Signal Transduction and Targeted Therapy 8:1.
Crossref
Tao Jiang, Linshuai Xing, Lipeng Zhao, Ziqi Ye, Dong Yu & Shengtao Lin. (2023) Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer. BMC Medical Genomics 16:1.
Crossref
Ping Luo, Shiqi Li & Xinghua Long. (2023) N6-methyladenosine RNA modification in PD-1/PD-L1: Novel implications for immunotherapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:3, pages 188873.
Crossref
Linchuan Gan, Yuxiang Zhao, Yajuan Fu & Qi Chen. (2023) The potential role of m6A modifications on immune cells and immunotherapy. Biomedicine & Pharmacotherapy 160, pages 114343.
Crossref
Li Liu, Long Liang, Hui Li, Wenjun Shao, Chaoying Yang, Feng Lin, Jing Liu & Ji Zhang. (2023) The role of m6A-mediated PD-1/PD-L1 in antitumor immunity. Biochemical Pharmacology 210, pages 115460.
Crossref
Lin Chen, Yang Gao, Simiao Xu, Jinxiong Yuan, Min Wang, Tianyu Li & Jun Gong. (2023) N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms. Frontiers in Immunology 14.
Crossref
Juan Pan, Tuxiong Huang, Zhenjun Deng & Chang Zou. (2023) Roles and therapeutic implications of m6A modification in cancer immunotherapy. Frontiers in Immunology 14.
Crossref
Shuang Li, Hui Liu, Zhe Ruan, Rongjing Guo, Chao Sun, Yonglan Tang, Xiaoxi Huang, Ting Gao, Sijia Hao, Huanhuan Li, Na Song, Yue Su, Fan Ning, Zhuyi Li & Ting Chang. (2023) Landscape analysis of m6A modification regulators related biological functions and immune characteristics in myasthenia gravis. Journal of Translational Medicine 21:1.
Crossref
Wei Yu, Jinti Lin, Tao Yu, Jianan Lou, Chao Qian, Ankai Xu, Bing Liu, Huimin Tao & Libin Jin. (2023) The regulation of N6 ‐methyladenosine modification in PD‐L1 ‐induced anti‐tumor immunity . Immunology & Cell Biology 101:3, pages 204-215.
Crossref
Xianyong Zhou, Chen Li, Tong Chen, Wenhao Li, Xiaolong Wang & Qifeng Yang. (2023) Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. Molecular Cancer 22:1.
Crossref
Yanan Zhu, Jing Li, Hang Yang, Xinyi Yang, Ya Zhang, Xinchao Yu, Ying Li, Gangxian Chen & Zuozhang Yang. (2023) The potential role of m6A reader YTHDF1 as diagnostic biomarker and the signaling pathways in tumorigenesis and metastasis in pan-cancer. Cell Death Discovery 9:1.
Crossref
Chengdong Liu, Wanli Zhang, Xiaohan Zhou & Li Liu. (2022) IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma. Frontiers in Immunology 13.
Crossref
Zaoqu Liu, Haijiao Zou, Qin Dang, Hui Xu, Long Liu, Yuyuan Zhang, Jinxiang Lv, Huanyun Li, Zhaokai Zhou & Xinwei Han. (2022) Biological and pharmacological roles of m6A modifications in cancer drug resistance. Molecular Cancer 21:1.
Crossref
Xinxin Li, Shoubao Ma, Youcai Deng, Ping Yi & Jianhua Yu. (2022) Targeting the RNA m6A modification for cancer immunotherapy. Molecular Cancer 21:1.
Crossref
Young Wha Koh, Jae-Ho Han, Seokjin Haam & Hyun Woo Lee. (2022) Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. Frontiers in Oncology 12.
Crossref
Zhangci Su, Leyao Xu, Xinning Dai, Mengyao Zhu, Xiaodan Chen, Yuanyuan Li, Jie Li, Ruihan Ge, Bin Cheng & Yun Wang. (2022) Prognostic and clinicopathological value of m6A regulators in human cancers: a meta-analysis. Aging 14:21, pages 8818-8838.
Crossref
Xinyu Zhang & Xinsheng Cai. (2022) Potential impact of WTAP and YTHDF2 on tumor immunity in lung adenocarcinoma. Medicine 101:45, pages e31195.
Crossref
Xue Chen, Xiaoliang Tong, Lu Zhou, Jian Huang, Lihua Gao, Jinrong Zeng & Lina Tan. (2022) Critical role of m6A modification in T-helper cell disorders. Molecular Immunology 151, pages 1-10.
Crossref
Kazuo Tsuchiya, Katsuhiro Yoshimura, Yuji Iwashita, Yusuke Inoue, Tsutomu Ohta, Hirofumi Watanabe, Hidetaka Yamada, Akikazu Kawase, Masayuki Tanahashi, Hiroshi Ogawa, Kazuhito Funai, Kazuya Shinmura, Takafumi Suda & Haruhiko Sugimura. (2022) m6A demethylase ALKBH5 promotes tumor cell proliferation by destabilizing IGF2BPs target genes and worsens the prognosis of patients with non-small-cell lung cancer. Cancer Gene Therapy 29:10, pages 1355-1372.
Crossref
Lian Cui, Rui Ma, Jiangluyi Cai, Chunyuan Guo, Zeyu Chen, Lingling Yao, Yuanyuan Wang, Rui Fan, Xin Wang & Yuling Shi. (2022) RNA modifications: importance in immune cell biology and related diseases. Signal Transduction and Targeted Therapy 7:1.
Crossref
Chengchi Huang, Peng Qi, Hao Cui, Qun Lu & Xue Gao. (2022) CircFAT1 regulates retinal pigment epithelial cell pyroptosis and autophagy via mediating m6A reader protein YTHDF2 expression in diabetic retinopathy. Experimental Eye Research 222, pages 109152.
Crossref
Huihui Ji, Jian-an Zhang, Hejing Liu, Kehan Li, Zhi-wei Wang & Xueqiong Zhu. (2022) Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer. Frontiers in Immunology 13.
Crossref
Heng Yang, Chengyao Chiang, Qinhong Luo, Chunlan Chen, Junrong Huang, Lizhi Zhu & Duo Zheng. (2022) YT521-B homology domain family proteins as N6-methyladenosine readers in tumors. Frontiers in Genetics 13.
Crossref
Zhen Fang, Wentong Mei, Chang Qu, Jiongdi Lu, Liang Shang, Feng Cao & Fei Li. (2022) Role of m6A writers, erasers and readers in cancer. Experimental Hematology & Oncology 11:1.
Crossref
Jing Xu, Yan Shang, Xiong Qin, Yun Gai, Feng Cai, Hua Xiao, Chen Zhou, Youhui Fu & Xiahui Ge. (2022) N6-Methyladenosine Reader YTHDF2 Enhances Non-Small-Cell Lung Cancer Cell Proliferation and Metastasis through Mediating circ_SFMBT2 Degradation. Contrast Media & Molecular Imaging 2022, pages 1-12.
Crossref
Fan Chen, Xuan Xie, Min Chao, Haiyan Cao & Liang Wang. (2022) The Potential Value of m6A RNA Methylation in the Development of Cancers Focus on Malignant Glioma. Frontiers in Immunology 13.
Crossref
Xiaomin Chen, Xiangxiang Zhou & Xin Wang. (2022) m6A binding protein YTHDF2 in cancer. Experimental Hematology & Oncology 11:1.
Crossref
Qiang Liu. (2022) Current Advances in N6-Methyladenosine Methylation Modification During Bladder Cancer. Frontiers in Genetics 12.
Crossref
Huan Tong, He Wei, Alhaji Osman Smith & Juan Huang. (2022) The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Liting Guo, Hui Yang, Chenfei Zhou, Yan Shi, Lei Huang & Jun Zhang. (2021) N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy. Frontiers in Immunology 12.
Crossref
Chen Chen, Yuying Guo, Yaxin Guo, Xiaoke Wu, Chaohua Si, Yanxin Xu, Qiaozhen Kang & Zhenqiang Sun. (2021) m6A Modification in Non-Coding RNA: The Role in Cancer Drug Resistance. Frontiers in Oncology 11.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.